gamma-aminobutyric acid has been researched along with Cough in 28 studies
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.
Cough: A sudden, audible expulsion of air from the lungs through a partially closed glottis, preceded by inhalation. It is a protective response that serves to clear the trachea, bronchi, and/or lungs of irritants and secretions, or to prevent aspiration of foreign materials into the lungs.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Adults with refractory chronic cough (>8 weeks' duration) without active respiratory disease or infection were randomly assigned to receive gabapentin (maximum tolerable daily dose of 1800 mg) or matching placebo for 10 weeks." | 9.16 | Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial. ( Birring, SS; Gibson, PG; Ryan, NM, 2012) |
| " Gabapentin significantly improved cough-specific quality of life compared with placebo (between-group difference in LCQ score during treatment period 1·80, 95% CI 0·56-3·04; p=0·004; number needed to treat of 3·58)." | 9.16 | Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial. ( Birring, SS; Gibson, PG; Ryan, NM, 2012) |
| "The treatment of refractory chronic cough with gabapentin is both effective and well tolerated." | 9.16 | Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial. ( Birring, SS; Gibson, PG; Ryan, NM, 2012) |
| "Recent developments in the treatment of cough include the use of speech pathology and pharmacotherapy with gabapentin." | 8.91 | Gabapentin in chronic cough. ( Gibson, PG; Vertigan, AE, 2015) |
| "The effectiveness of neuromodulating medications such as gabapentin and pregabalin in the treatment of cough has been supported primarily through case series, case reports, prospective reviews and a double blind randomised controlled trial." | 8.91 | Gabapentin in chronic cough. ( Gibson, PG; Vertigan, AE, 2015) |
| "Response to gabapentin was defined by physician-documented subjective patient report of improvement in cough symptoms." | 7.85 | Unilateral Laryngoscopic Findings Associated With Response to Gabapentin in Patients With Chronic Cough. ( Dibildox, D; Giliberto, JP; Merati, A, 2017) |
| " Therapy was initiated in patients with chronic cough with gabapentin, 100 mg twice daily, which was titrated to response or adverse effects." | 7.85 | Unilateral Laryngoscopic Findings Associated With Response to Gabapentin in Patients With Chronic Cough. ( Dibildox, D; Giliberto, JP; Merati, A, 2017) |
| "In patients with chronic cough suspected to be related to vagal neuropathy, the odds of response to gabapentin are higher with the presence of VFMA noted on videostroboscopy." | 7.85 | Unilateral Laryngoscopic Findings Associated With Response to Gabapentin in Patients With Chronic Cough. ( Dibildox, D; Giliberto, JP; Merati, A, 2017) |
| "Gabapentin has been shown to cause minimal to no toxicity in overdose." | 6.52 | A review on the efficacy and safety of gabapentin in the treatment of chronic cough. ( Ryan, NM, 2015) |
| "Recent developments in the treatment of cough include the use of speech pathology and pharmacotherapy with gabapentin." | 6.52 | Gabapentin in chronic cough. ( Gibson, PG; Vertigan, AE, 2015) |
| "Chronic cough is regarded as a challenging clinical problem due to its frequency and often limited therapeutic options." | 6.52 | Gabapentin in chronic cough. ( Gibson, PG; Vertigan, AE, 2015) |
| "Chronic cough is a debilitating, often multifactorial problem." | 5.46 | Unilateral Laryngoscopic Findings Associated With Response to Gabapentin in Patients With Chronic Cough. ( Dibildox, D; Giliberto, JP; Merati, A, 2017) |
| " Adults with refractory chronic cough (>8 weeks' duration) without active respiratory disease or infection were randomly assigned to receive gabapentin (maximum tolerable daily dose of 1800 mg) or matching placebo for 10 weeks." | 5.16 | Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial. ( Birring, SS; Gibson, PG; Ryan, NM, 2012) |
| " Gabapentin significantly improved cough-specific quality of life compared with placebo (between-group difference in LCQ score during treatment period 1·80, 95% CI 0·56-3·04; p=0·004; number needed to treat of 3·58)." | 5.16 | Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial. ( Birring, SS; Gibson, PG; Ryan, NM, 2012) |
| "The treatment of refractory chronic cough with gabapentin is both effective and well tolerated." | 5.16 | Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial. ( Birring, SS; Gibson, PG; Ryan, NM, 2012) |
| "Recent developments in the treatment of cough include the use of speech pathology and pharmacotherapy with gabapentin." | 4.91 | Gabapentin in chronic cough. ( Gibson, PG; Vertigan, AE, 2015) |
| "The effectiveness of neuromodulating medications such as gabapentin and pregabalin in the treatment of cough has been supported primarily through case series, case reports, prospective reviews and a double blind randomised controlled trial." | 4.91 | Gabapentin in chronic cough. ( Gibson, PG; Vertigan, AE, 2015) |
| "The goal of this systematic review was to examine the evidence for the use of the neuromodulating agents, amitriptyline, gabapentin, pregabalin, and baclofen, in the management of chronic, idiopathic cough patients." | 4.89 | Use of specific neuromodulators in the treatment of chronic, idiopathic cough: a systematic review. ( Cohen, SM; Misono, S, 2013) |
| "Benefit from neuromodulator treatment with amitriptyline, gabapentin, pregabalin, and baclofen in chronic, idiopathic cough patients was demonstrated." | 4.89 | Use of specific neuromodulators in the treatment of chronic, idiopathic cough: a systematic review. ( Cohen, SM; Misono, S, 2013) |
| "Response to gabapentin was defined by physician-documented subjective patient report of improvement in cough symptoms." | 3.85 | Unilateral Laryngoscopic Findings Associated With Response to Gabapentin in Patients With Chronic Cough. ( Dibildox, D; Giliberto, JP; Merati, A, 2017) |
| " Therapy was initiated in patients with chronic cough with gabapentin, 100 mg twice daily, which was titrated to response or adverse effects." | 3.85 | Unilateral Laryngoscopic Findings Associated With Response to Gabapentin in Patients With Chronic Cough. ( Dibildox, D; Giliberto, JP; Merati, A, 2017) |
| "In patients with chronic cough suspected to be related to vagal neuropathy, the odds of response to gabapentin are higher with the presence of VFMA noted on videostroboscopy." | 3.85 | Unilateral Laryngoscopic Findings Associated With Response to Gabapentin in Patients With Chronic Cough. ( Dibildox, D; Giliberto, JP; Merati, A, 2017) |
| "Gabapentin has been shown to cause minimal to no toxicity in overdose." | 2.52 | A review on the efficacy and safety of gabapentin in the treatment of chronic cough. ( Ryan, NM, 2015) |
| "Recent developments in the treatment of cough include the use of speech pathology and pharmacotherapy with gabapentin." | 2.52 | Gabapentin in chronic cough. ( Gibson, PG; Vertigan, AE, 2015) |
| "Chronic cough is regarded as a challenging clinical problem due to its frequency and often limited therapeutic options." | 2.52 | Gabapentin in chronic cough. ( Gibson, PG; Vertigan, AE, 2015) |
| "Chronic refractory cough has factors in common with laryngeal hypersensitivity syndromes and chronic pain syndromes, and these similarities help to shed light on the pathophysiology of the condition." | 2.52 | Management of chronic refractory cough. ( Gibson, PG; Vertigan, AE, 2015) |
| "Chronic cough is a debilitating, often multifactorial problem." | 1.46 | Unilateral Laryngoscopic Findings Associated With Response to Gabapentin in Patients With Chronic Cough. ( Dibildox, D; Giliberto, JP; Merati, A, 2017) |
| "Chronic cough is often attributed to reflux, postnasal drip, or asthma." | 1.33 | Chronic cough as a sign of laryngeal sensory neuropathy: diagnosis and treatment. ( Lee, B; Woo, P, 2005) |
| "Cough and laryngospasm were the most common complaints." | 1.33 | Chronic cough as a sign of laryngeal sensory neuropathy: diagnosis and treatment. ( Lee, B; Woo, P, 2005) |
| "Cough is a prominent symptom of pulmonary disease, but the effects of GABAB agonists on this airway reflex are unknown." | 1.29 | Antitussive effects of GABAB agonists in the cat and guinea-pig. ( Aziz, SM; Bolser, DC; Chapman, RW; DeGennaro, FC; Egan, RW; Kreutner, W; Siegel, MI, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.57) | 18.7374 |
| 1990's | 3 (10.71) | 18.2507 |
| 2000's | 5 (17.86) | 29.6817 |
| 2010's | 19 (67.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Giliberto, JP | 2 |
| Dibildox, D | 1 |
| Merati, A | 1 |
| Kotmanova, Z | 1 |
| Simera, M | 1 |
| Veternik, M | 1 |
| Martvon, L | 1 |
| Misek, J | 1 |
| Jakus, J | 1 |
| Shen, TY | 1 |
| Musselwhite, MN | 1 |
| Pitts, T | 1 |
| Bolser, DC | 3 |
| Poliacek, I | 1 |
| El-Hashim, AZ | 1 |
| Mathews, S | 1 |
| Al-Shamlan, F | 1 |
| Abdulqawi, R | 1 |
| Woodcock, A | 1 |
| Smith, JA | 1 |
| Brown, JP | 1 |
| Bhowmik, A | 1 |
| Inoue, K | 1 |
| Takano, H | 1 |
| Ryan, NM | 3 |
| Birring, SS | 2 |
| Gibson, PG | 4 |
| Wu, CH | 1 |
| Gunasekara, K | 1 |
| Hull, JH | 1 |
| Bikov, A | 1 |
| Morris, AJ | 1 |
| Usmani, OS | 1 |
| Vertigan, AE | 2 |
| Bonnet, U | 1 |
| Ossowski, A | 1 |
| Schubert, M | 1 |
| Gall, H | 1 |
| Steinkamp, I | 1 |
| Richter, LE | 1 |
| Khalil-Boutros, Y | 1 |
| Nefedev, A | 1 |
| Kuhlmann, R | 1 |
| Cohen, SM | 2 |
| Misono, S | 2 |
| Greene, SM | 1 |
| Simpson, CB | 1 |
| Norris, BK | 1 |
| Schweinfurth, JM | 1 |
| Canning, BJ | 1 |
| Mori, N | 1 |
| Chung, KF | 1 |
| Lee, B | 1 |
| Woo, P | 1 |
| Persaud, R | 1 |
| Frosh, A | 1 |
| Mintz, S | 2 |
| Lee, JK | 2 |
| Mishriki, YY | 1 |
| Aziz, SM | 1 |
| DeGennaro, FC | 1 |
| Kreutner, W | 1 |
| Egan, RW | 1 |
| Siegel, MI | 1 |
| Chapman, RW | 2 |
| Hey, JA | 1 |
| Rizzo, CA | 1 |
| Callaway, JK | 1 |
| King, RG | 1 |
| Nosál'ová, G | 1 |
| Varonos, D | 1 |
| Papadopoulou-Daifotis, Z | 1 |
7 reviews available for gamma-aminobutyric acid and Cough
| Article | Year |
|---|---|
A review on the efficacy and safety of gabapentin in the treatment of chronic cough.
Topics: Amines; Antitussive Agents; Chronic Disease; Cough; Cyclohexanecarboxylic Acids; Gabapentin; gamma-A | 2015 |
Gabapentin in chronic cough.
Topics: Amines; Animals; Chronic Disease; Cough; Cyclohexanecarboxylic Acids; Excitatory Amino Acid Antagoni | 2015 |
Management of chronic refractory cough.
Topics: Adaptation, Psychological; Amines; Chronic Disease; Cough; Cyclohexanecarboxylic Acids; Gabapentin; | 2015 |
Are neuromodulating medications effective for the treatment of chronic neurogenic cough?
Topics: Amines; Amitriptyline; Chronic Disease; Cough; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminob | 2017 |
Evidence for sensory neuropathy and pharmacologic management.
Topics: Adrenergic Uptake Inhibitors; Amines; Amitriptyline; Anticonvulsants; Chronic Disease; Cough; Cycloh | 2010 |
Use of specific neuromodulators in the treatment of chronic, idiopathic cough: a systematic review.
Topics: Amines; Amitriptyline; Baclofen; Chronic Disease; Cough; Cyclohexanecarboxylic Acids; Gabapentin; ga | 2013 |
GABAB receptors in the lung.
Topics: Anaphylaxis; Animals; Baclofen; Cough; gamma-Aminobutyric Acid; Humans; Lung; Neurons, Afferent; Par | 1993 |
1 trial available for gamma-aminobutyric acid and Cough
| Article | Year |
|---|---|
Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Amines; Anticonvulsants; Central Nervous System; Chronic Disease; Cough; Cyclohex | 2012 |
20 other studies available for gamma-aminobutyric acid and Cough
| Article | Year |
|---|---|
Unilateral Laryngoscopic Findings Associated With Response to Gabapentin in Patients With Chronic Cough.
Topics: Amines; Calcium Channel Blockers; Chronic Disease; Cough; Cyclohexanecarboxylic Acids; Female; Gabap | 2017 |
GABA-ergic neurotransmission in the nucleus of the solitary tract modulates cough in the cat.
Topics: Animals; Baclofen; Blood Pressure; Cats; Cough; Esophagus; gamma-Aminobutyric Acid; Heart Rate; Inha | 2018 |
Central adenosine A
Topics: Adenosine; Adenosine A1 Receptor Agonists; Adenosine A1 Receptor Antagonists; Administration, Inhala | 2018 |
Gabapentin for refractory chronic cough.
Topics: Amines; Cough; Cyclohexanecarboxylic Acids; Female; gamma-Aminobutyric Acid; Humans; Male; Neurotran | 2013 |
Gabapentin for refractory chronic cough.
Topics: Amines; Cough; Cyclohexanecarboxylic Acids; Female; gamma-Aminobutyric Acid; Humans; Male; Neurotran | 2013 |
Gabapentin for refractory chronic cough.
Topics: Amines; Cough; Cyclohexanecarboxylic Acids; Female; gamma-Aminobutyric Acid; Humans; Male; Neurotran | 2013 |
Gabapentin for refractory chronic cough - Authors' reply.
Topics: Amines; Cough; Cyclohexanecarboxylic Acids; Female; gamma-Aminobutyric Acid; Humans; Male; Neurotran | 2013 |
Gabapentin as a potential treatment for cough syncope.
Topics: Amines; Antitussive Agents; Chronic Disease; Cough; Cyclohexanecarboxylic Acids; Gabapentin; gamma-A | 2015 |
[On the Differential Diagnosis of Intractable Psychogenic Chronic Cough: Neuropathic Larynx Irritable - Gabapentin's Antitussive Action].
Topics: Aged; Amines; Avitaminosis; Chronic Disease; Cough; Cyclohexanecarboxylic Acids; Depressive Disorder | 2015 |
Management of recurrent laryngeal sensory neuropathic symptoms.
Topics: Adrenergic Uptake Inhibitors; Aged; Amines; Amitriptyline; Cough; Cranial Nerve Diseases; Cyclohexan | 2010 |
Encoding of the cough reflex in anesthetized guinea pigs.
Topics: 4-Aminopyridine; 6-Cyano-7-nitroquinoxaline-2,3-dione; Anesthesia; Animals; Biphenyl Compounds; Citr | 2011 |
Gabapentin: a suppressant for refractory chronic cough.
Topics: Amines; Cough; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid; Humans; Mal | 2012 |
Chronic cough as a sign of laryngeal sensory neuropathy: diagnosis and treatment.
Topics: Adolescent; Adult; Aged; Amines; Analgesics; Cough; Cyclohexanecarboxylic Acids; Deglutition Disorde | 2005 |
The aetiology of chronic cough: a review of current theories for the otorhinolaryngologists.
Topics: Amines; Anticonvulsants; Chronic Disease; Cough; Cranial Nerve Diseases; Cyclohexanecarboxylic Acids | 2006 |
Gabapentin in the treatment of intractable idiopathic chronic cough: case reports.
Topics: Adult; Aged; Amines; Calcium Channel Blockers; Chronic Disease; Cough; Cyclohexanecarboxylic Acids; | 2006 |
Chronic cough as a sign of laryngeal sensory neuropathy: diagnosis and treatment.
Topics: Amines; Chronic Disease; Cough; Cranial Nerve Diseases; Cyclohexanecarboxylic Acids; Diagnosis, Diff | 2006 |
Laryngeal neuropathy as a cause of chronic intractable cough.
Topics: Amines; Cough; Cyclohexanecarboxylic Acids; Excitatory Amino Acid Antagonists; Gabapentin; gamma-Ami | 2007 |
Antitussive effects of GABAB agonists in the cat and guinea-pig.
Topics: Animals; Antitussive Agents; Baclofen; Capsaicin; Cats; Codeine; Cough; Dextromethorphan; Electromyo | 1993 |
Effects of inhaled alpha 2-adrenoceptor and GABAB receptor agonists on citric acid-induced cough and tidal volume changes in guinea pigs.
Topics: Acetylcholine; Administration, Inhalation; Adrenergic alpha-Agonists; Animals; Atropine; Azepines; B | 1992 |
[Cough and central GABAergic mechanisms].
Topics: Animals; Cats; Cough; gamma-Aminobutyric Acid | 1986 |